TrialBMC cancer2014

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.

Janne B Kjersem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.